Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Ltd ADR (NQ: ATHE )

2.880 +0.070 (+2.49%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,960
Open 2.790
Bid (Size) 2.790 (2)
Ask (Size) 2.890 (1)
Prev. Close 2.810
Today's Range 2.790 - 2.880
52wk Range 2.520 - 7.900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire

Performance

YTD
-21.05%
-21.05%
1 Month
-0.88%
-0.88%
3 Month
-12.73%
-12.73%
6 Month
-17.71%
-17.71%
1 Year
-59.15%
-59.15%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity's Parkinson's Candidate Prevents Loss Of Brain Cells In Animal Model
Via Benzinga
Here's Why Alterity Therapeutics Shares Are Moving
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Here's Why Alterity Therapeutics Shares Are Volatile
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.